ArticleiScience2026
ZDHHC17-mediated IKKβ palmitoylation suppresses NF-κB signaling to mitigate the progression of liver fibrosis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis (LF) is a common consequence of chronic liver injury and inflammation, driven by the IKK complex-mediated NF-κB signaling pathway. This study investigated the role of macrophage IKKβ palmitoylation in NF-κB signaling and LF progression. Analysis of liver tissues and peripheral blood mononuclear cells (PBMCs) from LF patients and healthy individuals revealed decreased ZDHHC17 expression in LF-associated macrophages. Using mouse models of LF and ZDHHC17 knockout mice, we found that ZDHHC17 deficiency accelerated LF progression. Mechanistically, ZDHHC17 palmitoylated IKKβ at cysteine 299, inhibiting its autophosphorylation and NF-κB pathway activation. This suppression reduced macrophage inflammatory responses and hepatic stellate cell activation, mitigating LF. Additionally, IKKβ palmitoylation weakened its interaction with TAK1, reducing phosphorylation at Ser177 and Ser181, further inhibiting NF-κB signaling. These findings highlight ZDHHC17 as a key regulator of IKKβ palmitoylation, suppressing inflammation, and LF progression. Targeting IKKβ palmitoylation may offer a novel therapeutic approach for LF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.